Skip to content

Study · Systematic review · 2024

2 results

Intentional weight loss in overweight and obese patients with heart failure: A systematic review.

Peck KH, Dulay MS, Hameed S, Rosano G, Tan T, Dar O

European journal of heart failure16 May 2024Cited by 15 (Europe PMC)

PMID38752254 (opens in a new tab)DOI10.1002/ejhf.3270 (opens in a new tab)PepBankPUB-38752254
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of intentional weight loss in heart failure with obesity, semaglutide resulted in weight loss.

    In plain wordsIn a review of weight loss in people with heart failure and obesity, semaglutide led to weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in obese heart failure patients
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide resulted in weight loss with improvement in QOL.
    1 context sentence
    Summary · context
    All studies had moderate to high risk of bias except one randomized controlled trial (RCT) which evaluated semaglutide in HF with preserved ejection fraction (HFpEF) patients.
  2. 02HumanSystematic reviewEfficacy outcome

    In a systematic review of intentional weight loss in heart failure with obesity, semaglutide resulted in improvement in quality of life.

    In plain wordsIn a review of weight loss in people with heart failure and obesity, semaglutide improved quality of life.

    Peptide
    Semaglutide
    Outcome
    IncreaseQuality of life in obese heart failure patients
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide resulted in weight loss with improvement in QOL.
    1 context sentence
    Summary · context
    All studies had moderate to high risk of bias except one randomized controlled trial (RCT) which evaluated semaglutide in HF with preserved ejection fraction (HFpEF) patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.